Erbitux Approval History

• FDA approved: Yes (First approved February 12th, 2004)
• Brand name: Erbitux
• Generic name: cetuximab
• Dosage form: Injection
• Company: ImClone
• Treatment for: Colorectal Cancer, Head and Neck Cancer

Erbitux is epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of colorectal cancer and Head and Neck Cancer.

Development History and FDA Approval Process for Erbitux

Date	Article
Nov  7, 2011	FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer
Dec  8, 2008	Erbitux Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Oct 31, 2008	Erbitux Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration
Sep  3, 2008	ImClone Submits Supplemental Biologics License Application for Erbitux in First-Line Head and Neck Cancer
Sep  4, 2007	Merck Applies to Extend Use of Erbitux for 1st-Line Colorectal Cancer
Jun 11, 2007	FDA Accepts and Grants Priority Review of Erbitux (Cetuximab) sBLA for Overall Survival in Patients With Advanced Colorectal Cancer
Aug 30, 2005	ImClone Systems Incorporated and Bristol-Myers Squibb File Supplemental Biologics License Application for Erbitux for Treatment of Head and Neck Cancer
Feb 12, 2004	Erbitux ImClone - Treatment for Advanced Colorectal Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.